Novo Nordisk: Continued Concerns Of Compounding
Summary
- We sold Novo Nordisk out of the portfolio due to two concerns that made us question the company’s ability to deliver long-term growth.
- There were two incidents of suicide out of total 3,008 patients in CagriSema’s Phase 3 trials.
- Together with the continued concerns of compounding, which is a blatant violation of intellectual property and proven to be more difficult to rein in, we decided to exit the position.
Select quarterly mutual fund commentaries.
